Fluconazole
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fluconazole: From Antifungal Therapy to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Fluconazole is a triazole antifungal agent; detailed data on its originally licensed indication were not provided in this evidence pack. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, but currently no clinical trials and no published literature support this specific direction — the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the source data (Fluconazole is a triazole antifungal; specific licensed indication text was not supplied in this pack) |
| Predicted New Indication | Punctate Epithelial Keratoconjunctivitis |
| TxGNN Prediction Score | 99.24% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available for this candidate (flagged as a High-severity data gap in the evidence pack). Based on known pharmacology, fluconazole inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis in the fungal cell membrane — an antifungal mechanism.
Punctate epithelial keratoconjunctivitis, however, is most commonly caused by viral pathogens (e.g. adenovirus), not fungal organisms. A theoretical mechanistic link to fluconazole would only apply in the rare setting of fungal keratitis, and even that link is not substantiated by any trial or literature evidence in this pack.
As a result, this prediction should be regarded as a raw TxGNN model score without corroborating clinical or mechanistic support. It does not currently meet the bar for further pharmacological rationale beyond the model output itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisation is currently on record for Fluconazole in this data set (market status: Not Marketed; 0 authorisations).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trial or literature evidence supports fluconazole use in punctate epithelial keratoconjunctivitis, and the underlying mechanistic rationale is weak (the condition is predominantly viral, not fungal, in aetiology). The prediction score alone (L5, model-only) is insufficient to justify further development at this time.
To proceed, the following is needed:
- Mechanism of action (MOA) data for fluconazole (currently a blocking/high-severity data gap)
- UK product label warnings and contraindications (SmPC), currently unavailable — this is a blocking gap for any safety assessment
- Confirmation of UK marketing authorisation status, or an alternative licensed product route, given fluconazole is currently unmarketed in this data set
- Note: other candidates in this evidence pack — notably pneumocystosis (Evidence Level L3, decision stage S1, 7 clinical trials and 20 publications identified) — show materially stronger supporting evidence and may warrant a separate, dedicated evaluation report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.